Santhera Pharmaceuticals Holding AG (SIX: SANN.SW) Stock Competitors & Peer Comparison
See SANN.SW's competitors and their performance on the SIX and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for SANN.SW and its SIX peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SANN.SW | CHF 13.84 | -1.98% | 211.8M | -6.07 | -CHF 2.28 | N/A |
| LONN.SW | CHF 631.80 | +0.57% | 44.1B | 39.66 | CHF 15.93 | +0.79% |
| BANB.SW | CHF 82.85 | +0.36% | 6.2B | 41.68 | CHF 1.99 | +1.09% |
| MOR.SW | CHF 102.00 | +0.00% | 2.4B | -4.03 | -CHF 25.33 | N/A |
| IDIA.SW | CHF 4.19 | -1.09% | 1.1B | -4.84 | -CHF 0.87 | N/A |
| BSLN.SW | CHF 68.50 | -1.15% | 848.8M | 16.13 | CHF 4.25 | N/A |
| NWRN.SW | CHF 8.64 | -0.46% | 176.7M | -6.41 | -CHF 1.35 | N/A |
| MOLN.SW | CHF 3.14 | +3.63% | 120.3M | -2.31 | -CHF 1.36 | N/A |
| RLF.SW | CHF 2.89 | +0.87% | 36.3M | -2.12 | -CHF 1.36 | N/A |
| MMTX.SW | CHF 0.16 | +5.12% | 27.2M | -0.67 | -CHF 0.24 | N/A |
Stock Comparison
Lonza Group AG (SIX: LONN.SW)
SANN.SW vs LONN.SW Comparison October 2026
Santhera Pharmaceuticals Holding AG (SIX: SANN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANN.SW stands at 211.8M. In comparison, LONN.SW has a market cap of 44.1B. Regarding current trading prices, SANN.SW is priced at CHF 13.84 on the SIX, while LONN.SW trades at CHF 631.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANN.SW currently has a P/E ratio of -6.07, whereas LONN.SW's P/E ratio is 39.66. In terms of profitability, SANN.SW's ROE is +3.55%, compared to LONN.SW's ROE of -0.01%. Regarding short-term risk, SANN.SW is more volatile compared to LONN.SW. This indicates higher risk in terms of short-term price fluctuations for SANN.SW.Check LONN.SW's competition here
Bachem Holding AG (SIX: BANB.SW)
SANN.SW vs BANB.SW Comparison October 2026
Santhera Pharmaceuticals Holding AG (SIX: SANN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANN.SW stands at 211.8M. In comparison, BANB.SW has a market cap of 6.2B. Regarding current trading prices, SANN.SW is priced at CHF 13.84 on the SIX, while BANB.SW trades at CHF 82.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANN.SW currently has a P/E ratio of -6.07, whereas BANB.SW's P/E ratio is 41.68. In terms of profitability, SANN.SW's ROE is +3.55%, compared to BANB.SW's ROE of +0.10%. Regarding short-term risk, SANN.SW is more volatile compared to BANB.SW. This indicates higher risk in terms of short-term price fluctuations for SANN.SW.Check BANB.SW's competition here
MorphoSys AG (SIX: MOR.SW)
SANN.SW vs MOR.SW Comparison October 2026
Santhera Pharmaceuticals Holding AG (SIX: SANN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANN.SW stands at 211.8M. In comparison, MOR.SW has a market cap of 2.4B. Regarding current trading prices, SANN.SW is priced at CHF 13.84 on the SIX, while MOR.SW trades at CHF 102.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANN.SW currently has a P/E ratio of -6.07, whereas MOR.SW's P/E ratio is -4.03. In terms of profitability, SANN.SW's ROE is +3.55%, compared to MOR.SW's ROE of -1.84%. Regarding short-term risk, SANN.SW is not fully comparable compared to MOR.SW. This indicates unavailable risk data in terms of short-term price fluctuations for SANN.SW.Check MOR.SW's competition here
Idorsia Ltd (SIX: IDIA.SW)
SANN.SW vs IDIA.SW Comparison October 2026
Santhera Pharmaceuticals Holding AG (SIX: SANN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANN.SW stands at 211.8M. In comparison, IDIA.SW has a market cap of 1.1B. Regarding current trading prices, SANN.SW is priced at CHF 13.84 on the SIX, while IDIA.SW trades at CHF 4.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANN.SW currently has a P/E ratio of -6.07, whereas IDIA.SW's P/E ratio is -4.84. In terms of profitability, SANN.SW's ROE is +3.55%, compared to IDIA.SW's ROE of +0.27%. Regarding short-term risk, SANN.SW is more volatile compared to IDIA.SW. This indicates higher risk in terms of short-term price fluctuations for SANN.SW.Check IDIA.SW's competition here
Basilea Pharmaceutica AG (SIX: BSLN.SW)
SANN.SW vs BSLN.SW Comparison October 2026
Santhera Pharmaceuticals Holding AG (SIX: SANN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANN.SW stands at 211.8M. In comparison, BSLN.SW has a market cap of 848.8M. Regarding current trading prices, SANN.SW is priced at CHF 13.84 on the SIX, while BSLN.SW trades at CHF 68.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANN.SW currently has a P/E ratio of -6.07, whereas BSLN.SW's P/E ratio is 16.13. In terms of profitability, SANN.SW's ROE is +3.55%, compared to BSLN.SW's ROE of +0.36%. Regarding short-term risk, SANN.SW is more volatile compared to BSLN.SW. This indicates higher risk in terms of short-term price fluctuations for SANN.SW.Check BSLN.SW's competition here
Newron Pharmaceuticals S.p.A. (SIX: NWRN.SW)
SANN.SW vs NWRN.SW Comparison October 2026
Santhera Pharmaceuticals Holding AG (SIX: SANN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANN.SW stands at 211.8M. In comparison, NWRN.SW has a market cap of 176.7M. Regarding current trading prices, SANN.SW is priced at CHF 13.84 on the SIX, while NWRN.SW trades at CHF 8.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANN.SW currently has a P/E ratio of -6.07, whereas NWRN.SW's P/E ratio is -6.41. In terms of profitability, SANN.SW's ROE is +3.55%, compared to NWRN.SW's ROE of +2.58%. Regarding short-term risk, SANN.SW is more volatile compared to NWRN.SW. This indicates higher risk in terms of short-term price fluctuations for SANN.SW.Check NWRN.SW's competition here
Molecular Partners AG (SIX: MOLN.SW)
SANN.SW vs MOLN.SW Comparison October 2026
Santhera Pharmaceuticals Holding AG (SIX: SANN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANN.SW stands at 211.8M. In comparison, MOLN.SW has a market cap of 120.3M. Regarding current trading prices, SANN.SW is priced at CHF 13.84 on the SIX, while MOLN.SW trades at CHF 3.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANN.SW currently has a P/E ratio of -6.07, whereas MOLN.SW's P/E ratio is -2.31. In terms of profitability, SANN.SW's ROE is +3.55%, compared to MOLN.SW's ROE of -0.68%. Regarding short-term risk, SANN.SW is less volatile compared to MOLN.SW. This indicates lower risk in terms of short-term price fluctuations for SANN.SW.Check MOLN.SW's competition here
Relief Therapeutics Holding AG (SIX: RLF.SW)
SANN.SW vs RLF.SW Comparison October 2026
Santhera Pharmaceuticals Holding AG (SIX: SANN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANN.SW stands at 211.8M. In comparison, RLF.SW has a market cap of 36.3M. Regarding current trading prices, SANN.SW is priced at CHF 13.84 on the SIX, while RLF.SW trades at CHF 2.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANN.SW currently has a P/E ratio of -6.07, whereas RLF.SW's P/E ratio is -2.12. In terms of profitability, SANN.SW's ROE is +3.55%, compared to RLF.SW's ROE of -0.39%. Regarding short-term risk, SANN.SW is less volatile compared to RLF.SW. This indicates lower risk in terms of short-term price fluctuations for SANN.SW.Check RLF.SW's competition here
MindMaze Therapeutics Holding S.A. (SIX: MMTX.SW)
SANN.SW vs MMTX.SW Comparison October 2026
Santhera Pharmaceuticals Holding AG (SIX: SANN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANN.SW stands at 211.8M. In comparison, MMTX.SW has a market cap of 27.2M. Regarding current trading prices, SANN.SW is priced at CHF 13.84 on the SIX, while MMTX.SW trades at CHF 0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANN.SW currently has a P/E ratio of -6.07, whereas MMTX.SW's P/E ratio is -0.67. In terms of profitability, SANN.SW's ROE is +3.55%, compared to MMTX.SW's ROE of N/A. Regarding short-term risk, SANN.SW is less volatile compared to MMTX.SW. This indicates lower risk in terms of short-term price fluctuations for SANN.SW.Check MMTX.SW's competition here
Spexis AG (SIX: SPEX.SW)
SANN.SW vs SPEX.SW Comparison October 2026
Santhera Pharmaceuticals Holding AG (SIX: SANN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANN.SW stands at 211.8M. In comparison, SPEX.SW has a market cap of 3.9M. Regarding current trading prices, SANN.SW is priced at CHF 13.84 on the SIX, while SPEX.SW trades at CHF 0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANN.SW currently has a P/E ratio of -6.07, whereas SPEX.SW's P/E ratio is -0.15. In terms of profitability, SANN.SW's ROE is +3.55%, compared to SPEX.SW's ROE of N/A. Regarding short-term risk, SANN.SW is less volatile compared to SPEX.SW. This indicates lower risk in terms of short-term price fluctuations for SANN.SW.Check SPEX.SW's competition here
Addex Therapeutics Ltd (SIX: ADXN.SW)
SANN.SW vs ADXN.SW Comparison October 2026
Santhera Pharmaceuticals Holding AG (SIX: SANN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANN.SW stands at 211.8M. In comparison, ADXN.SW has a market cap of 2.8M. Regarding current trading prices, SANN.SW is priced at CHF 13.84 on the SIX, while ADXN.SW trades at CHF 0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANN.SW currently has a P/E ratio of -6.07, whereas ADXN.SW's P/E ratio is -0.40. In terms of profitability, SANN.SW's ROE is +3.55%, compared to ADXN.SW's ROE of -1.73%. Regarding short-term risk, SANN.SW is less volatile compared to ADXN.SW. This indicates lower risk in terms of short-term price fluctuations for SANN.SW.Check ADXN.SW's competition here
ObsEva S.A. (SIX: OBSN.SW)
SANN.SW vs OBSN.SW Comparison October 2026
Santhera Pharmaceuticals Holding AG (SIX: SANN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANN.SW stands at 211.8M. In comparison, OBSN.SW has a market cap of 140.6K. Regarding current trading prices, SANN.SW is priced at CHF 13.84 on the SIX, while OBSN.SW trades at CHF 0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANN.SW currently has a P/E ratio of -6.07, whereas OBSN.SW's P/E ratio is -0.00. In terms of profitability, SANN.SW's ROE is +3.55%, compared to OBSN.SW's ROE of -1.46%. Regarding short-term risk, SANN.SW is less volatile compared to OBSN.SW. This indicates lower risk in terms of short-term price fluctuations for SANN.SW.Check OBSN.SW's competition here
Polyphor AG (SIX: POLN.SW)
SANN.SW vs POLN.SW Comparison October 2026
Santhera Pharmaceuticals Holding AG (SIX: SANN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANN.SW stands at 211.8M. In comparison, POLN.SW has a market cap of 0. Regarding current trading prices, SANN.SW is priced at CHF 13.84 on the SIX, while POLN.SW trades at CHF 1.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANN.SW currently has a P/E ratio of -6.07, whereas POLN.SW's P/E ratio is -0.46. In terms of profitability, SANN.SW's ROE is +3.55%, compared to POLN.SW's ROE of -1.32%. Regarding short-term risk, SANN.SW is less volatile compared to POLN.SW. This indicates lower risk in terms of short-term price fluctuations for SANN.SW.Check POLN.SW's competition here
Cassiopea S.p.A. (SIX: SKIN.SW)
SANN.SW vs SKIN.SW Comparison October 2026
Santhera Pharmaceuticals Holding AG (SIX: SANN.SW) plays a significant role within the Healthcare sector. Its performance on the SIX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SANN.SW stands at 211.8M. In comparison, SKIN.SW has a market cap of 0. Regarding current trading prices, SANN.SW is priced at CHF 13.84 on the SIX, while SKIN.SW trades at CHF 35.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SANN.SW currently has a P/E ratio of -6.07, whereas SKIN.SW's P/E ratio is -28.13. In terms of profitability, SANN.SW's ROE is +3.55%, compared to SKIN.SW's ROE of -1.27%. Regarding short-term risk, SANN.SW is less volatile compared to SKIN.SW. This indicates lower risk in terms of short-term price fluctuations for SANN.SW.Check SKIN.SW's competition here